The Montana Cancer Consortium (MCC) is an independent, nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho, and Wyoming through National Cancer Institute (NCI) sponsored clinical research. MCC coordinates, supports and improves the activities of physicians and other cancer care professionals, cancer centers and hospitals across the service area to maximize patient access to the highest levels of cancer care with a focus on access to clinical trials. In addition, MCC helps to design and influence cancer care delivery research through continued participation that informs and speeds validated care innovations into clinical practice. The region has been characterized as `mega-rural' with limited access to care due to the vastness of the geography, lack of university-based treatment and research facilities, and lack of primary care providers. Montana, Idaho and Wyoming are home to seven, five, and one American Indian Reservations respectively, where issues of poverty, distance, and cultural taboos surrounding cancer care discussion and treatment create unique disparities to prevention, early diagnosis, treatment and survivorship of cancer. The overall goal of MCC is to increase access to clinical trials in the service area while improving the delivery of cancer care through research. This is accomplished through inclusiveness of membership, communication, education, a commitment to quality, and participation in national clinical trial initiatives. The MCC NCORP Community Site consists of 10 primary affiliate sites and nine sub-affiliates that collectively serve nearly two million residents in an area covering over 200,000 square miles. Membership includes 60 oncology investigators representing all cancer care specialty areas. MCC is a member in good standing with the four adult research bases, and is poised to provide and support expanded access to state-of-the-art cancer treatment, control, prevention, screening, surveillance and care delivery through NCI-sponsored clinical trials. Strong leadership, an involved network of member physicians and dedicated affiliate sites strengthens MCC as an NCORP Community Site.

Public Health Relevance

Montana Cancer Consortium exists to maximize access to clinical trials and research through centralized services and support for member physicians and affiliate sites that might not otherwise offer access to these critical opportunities. The uniquely rural and medically underserved population of Montana, Northern Idaho and Northern Wyoming offers stimulating challenges for implementing NCI-sponsored clinical trials and care delivery research. The collective experience of the affiliate sites in successful clinical trial enrollment and care delivery research in the vastly rural area will benefit NCORP's diversity and disparity goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
2UG1CA189872-06
Application #
9771796
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Russo, Sandra
Project Start
2014-08-09
Project End
2025-07-31
Budget Start
2019-08-09
Budget End
2020-07-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Montana Cancer Consortium
Department
Type
DUNS #
802713917
City
Billings
State
MT
Country
United States
Zip Code
59102
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
McWilliams, Robert R; Foster, Nathan R; Mahoney, Michelle R et al. (2017) North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 123:3494-3501
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527

Showing the most recent 10 out of 19 publications